CASI Pharmaceuticals names new chief financial officer
1 October 2018 -

CASI Pharmaceuticals Inc (Nasdaq: CASI), a biopharmaceutical company, announced on Friday that it has named George Chi as its new chief financial officer.

Chi most recently served as vice president of Finance at Flavors Holdings Inc. He led the global accounting function, including financial reporting, planning, treasury, investor relations, and tax and auditing with management responsibility for global sales in 90 countries. Prior to joining Flavor Holdings, he was Chief Financial Officer at BPL Plasma. Previously, Chi served as finance director at Unilever.

Dr Wei-Wu He, executive chairman of CASI Pharmaceuticals, said, 'I'm very pleased to announce George's appointment and welcome him to CASI. George joins us at an opportune time as our company prepares for the marketing and sales of our first oncology product in China. He will be integral to help transition the Company's financial operations to commercial stage as we launch EVOMELA and other additional products from our pipeline.'